Lausanne, Switzerland, May 5, 2020 – Galderma today announced the closing of the sale of Bübchen to Dallmann’s Pharma GmbH, a company of Katjes International GmbH & Co. KG.

Bübchen is a recognized skincare brand in Germany, with trusted products designed for babies and kids. This transaction follows the conclusion of the strategic review of the Bübchen business initiated by Galderma, as it has been increasingly seen that growth opportunities for the brand lie outside of Galderma’s enhanced strategic focus.

Under the terms of the agreement, Dallmann’s Pharma takes over the Bübchen business, including the Bübchen brand and its dedicated manufacturing plant located in Soest, Germany.

Galderma CEO Flemming Orsnkov said: “I am delighted we have identified the right partner to take over the Bübchen business. It brings a new German home with the right focus for the much-loved Bübchen brand and for the passionate teams behind it, where it will continue to thrive into the future.”

About Galderma

Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com.

Media Contact

Sébastien Cros, media@galderma.com